大会首页
关于大会
同期活动
演讲嘉宾
历届回顾
参展申请
展商中心
场馆介绍
联系我们
 
 
演讲嘉宾
 
邹全明教授
 
 
 
 
 
I. Education :
1999 Visiting
Scholar1988.09~1991.12M.D
1984.09~1987.07M.Sc
1980.09~1984.07Bachelor
Biopharmaceutical Research Institute, University of Hannover, Germany
Majoring in Immunology, TMMU, Chongqing City, P.R.China
Majoring in Zoonosis, Ji Lin University, Ji Lin Province, P.R.China
Veterinary Science, Southwest University, Chongqing City, P.R.China
II. Professional Experience:
2008~present  Director of State Research Center of Immuno-biological
Products
Technology Engeering
2004- present  Director of Chongqing Biopharmaceuticals Engeering Technology
Research Cente
1997- present  Professor, Director, Dept. of Clinic Microbiology &
Immunology, TMMU
1994-1999      Associate professor, Associate Director
Dept. of Clinic Microbiology & Immunology, TMMU
1991-1994      Lecturer Dept. of Immunology, TMMU
III. Research Interests:
A. Area of research:
The study of pathogenic mechanism and immune response of H.pylori and E.
coli O157: H7 (E.coli
O157) and vaccine research&developmnet.
B. Research focus
① Interactions among CD4+ cell, CD8+  cell and CD4+CD25+  Treg cells, Th1
cell, Th2 cell, Th17 cell and
cytokines,  such  as  IFN-γ,  TNF-α,  IL-8,  IL-4,  IL-12  in  order  to 
expand  chronic  H.pylori  infection mechanism.
② Carrying out H.pylori gene polymorphism and micro-evolution research. At
the same time, analyzing
cell  models  and  clinical  specimens  of  patients,  to  explore  the 
relationship  between  H.pylori-specific microRNA and occurrence of
gastrosis.
③ Based on screen&identification of H.pylori and E.coli O157 protective
antigen epitopes, carrying out
the preparation of H.pylori, E.coli O157 vaccines and specific antibody,
which there has been completed
the H.pylori vaccine clinical trials phase-Ⅲ with more than 5000 subjects.
C. Professional Committees and Appointments:
Member of Subjects Review Group of the Academic Degrees Committee, State
Council
Member of the 10th  Pharmacopoeia Commission of the People’s Republic of
China
Committee  member  of  Chinese  Medical  Science  Technology  Award  & 
Chinese  Medical  Science  for
Youth Award, May 2001- May 2004
Director of Chongqing Municipality Medical Biotechnology Association,Feb.
2002-Feb.2007
Vice President of Chongqing Municipality Healthy Natural Therapy Research
Association,sinceOct.2007
Consultant of Chongqing Municipality Science and Technology Mastermind,May
2008-May 2011
Quanming Zou’s CV-2011
D. Academic Achievements:
1. Grants:
Ongoing:
2009.01-2011.12    National Techonological Platform construction Project:
“ National Engineering Research Center for Immunological Products”
¥7000,000
 
2008.12-2010.12    Major National Science & Technology Specific Projects of
P.R.China
“The Lasting Research on Oral Restructuring H.pylori Vaccine” ¥5000,000
2008.12-2010.12    National “Significant New Drug Discovery” Special
Program(2009ZX09306-006)
“The Large-scale Manufacturing and Seperation and Purification Technology
Platform of the
E.coli and Yeast Restructuring Protein Drugs Vaccine” ¥12,000,000
 
2010.1-2012.12      National Natural Science Foundation project (30970116)
“The  Translocation  Mechancism  Research  on  the  Intestinal  Bleeding 
E.coli  0157:H7  Close
Adhesion Receptor, the Tir” ¥300,000
2009.10-2012.10    Scientific and Technological Achievements Transformation
Fu
“Genetic Engineering Streptococcus Caries Vaccine Research” ¥500,000
2006.01-2008.12    Major Program of Natural Science Foundation of
Chongqing(CSTC 2006BA5024)
“Molecular  designing.structuring  and  applied  research  on  new 
high-efficient  extracellular secretion expression vector pES2c system”  ¥
200,000
2006.09-2009.09    National Science and Technology Projects (2005DKA21202-1)
“Standardized classification and meta-analysis of common pathogenic
microorganismӴ320,000
2006.04-2010.12    Military medical Programs for Science and Technology
Development
“Manufacturing of Zhihe toxin R&D on therapeutic antibodies”
 
2009.01-2010.12    Major Project of Chinese National Programs for Fundamental
Research and Development(2009
CB522606)
“Research on theevolution of H.pylori” ¥300,000
2008.01-2010.12    National Natural Science Foundation 30770514
“Research on crystal structure and functions about E.coli O157 tight
adhesin extracellular domain and its receptor binding fragment compounds”
¥300,000
2008.01-2010.12    National Natural Science Foundation 30770113
“Research for immunoprotection effect and response mechanism of H.pylori
protective antigen
Th epitopes ¥320,000
 
2006.12-2010.12    National High-tech Research Development Plan 2006AA02A208
“Clinical research into H.pylori genetically engineering vaccine ¥2500,000
2006.12-2008.12    National High-tech Research Development Plan 2006AA02Z443
“Trial and pre-clinical research for E.coli O157 genetically engineering
vaccine” ¥3810,000
Quanming Zou’s CV-2011
2006.12-2008.12    National High-tech Research Development Plan 2006AA02Z405
“Research for EHEC O157: H7 humanized therapeutic antibody
develpomen¥1000,000
Completed:
2004.01-2005.12    Military   Science   Foundation     for   Outstanding    Scholarship
“Vaccine  Research  on  0157  genetic  engineering  enterohemorrhagic  E .
coli ( EHEC ) ”
¥200,000
2004.01-2005.12    Major   Program   for   Science   and   Technology  
Development   (  2003AA2Z3C64  ,
2005AA2Z3G00)
“Vaccine Research on oral use of H..pylori adjuvants” ¥1,300,000
2004.01-2005.12    The 10th Five Years Key Programs for Science and Technology
Development of P.R.China
(2003 AA215060)
“Study on the synthesis of genetic engineering H. pylori. Vaccine” ¥500,000
2001.12-2003.12    National High-tech Research Development Plan 2001AA215161
“Pilot research for H.pylori genetically engineering vaccine” ¥330,000
1998.03-2002.12    National Science and Technology Research Key Projects 
96-901-01-54
“Research for H.pylori bivalent subunit molecular adjuvant vaccine ”
¥1150,000
1998.08-2002.12    Chongqing Major scientific and technological projects
990601
“Research for H.pylori bivalent subunit vaccine” ¥3500,000
2002.10-2004.12    National Innovation Fund for Small and Medium Enterprises
02C26215110432
“Oral recombinant H.pylori vaccine”¥850,000
2. Selected Publications : Published (*Representative work):
1  * Xiao B, Liu Z, L i BS, Tang B, Li W, Guo G, Shi Y, Wang F, Wu Y, Tong
WD, Guo H, Mao XH, Zou QM. Induction of microRNA-155 during H.pylori
infection and its negative regulatory role in the inflammatory response. J
INFECT DIS. 2009; 200:916–25Xiao B, Li W, Guo G, Li BS, Liu Z, Jia KR, Guo
Y, Mao XH, Zou QM. Identification of small non-coding RNAs in H.pylori by a
bioinformatics based approach. Current Microbiology.
2009, 58(3):258-63.
2  Liu L, Zeng H, Luo P, Wu J, Chen H, Shi Y, Zhang W, Mao X, Xiao B, Zou
Q. Cloning a Truncated Fragment (stx2a(1)) of the Shiga-Like Toxin 2A (1)
Subunit of EHEC O157:H7: Candidate Immunogen for a Subunit Vaccine. Mol
Biotechnol. 2009 Sep;43(1):8-14
3  Hu Y, Jiang F, Guo Y, Shen X, Zhang Y, Zhang R, Guo G, Mao X, Zou Q,
Wang DC. Crystal structure of HugZ, a novel heme oxygenase from
Helicobacter pylori. J Biol Chem. 2010 Oct 28.
4  Liao YL, Guo G, Mao XH, Xie QH, Zhang WJ, Liu XF, Zou QM. Core Genome
Haplotype Diversity and
vacA Allelic Heterogeneity of Chinese H.pylori Strains. Curr Microbiol.
2009 Aug;59(2):123-9.
5  Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, Guo G, Li HX, Zou QM.Therapeutic
efficacy of a multi- epitope vaccine against H.pylori infection in BALB/c
mice model. Vaccine. 2009 Aug 6;27(36):5013-9
6  Jiang Gu, Yanqing Liu, Shu Yu, Haiguang Wang, Qingxu Wang, Yong Yi,
Fengcai Zhu, Xue-jie Yu, Quanming Zou, Xuhu Mao. Enterohemorrhagic
Escherichia coli; trivalent subunit vaccine; intimin, shiga toxin; E. coli
secreted protein A. Microbes and Infection. 2009 Sep;11(10-11):835-41.
Quanming Zou’s CV-2011
7  Yan Cheng, Youjun Feng, Ping Luo, et al. Fusion expression and
immunogenicity of EHEC EspA-Stx2A1
protein: Implications for the vaccine development. J Microbiology, 2009,
47(4):498-505
8  Xiao B, Li W, Yang J, Guo G, Mao XH, Zou QM. RGD-IL-24, A Novel
Tumor-Targeted Fusion Cytokine: Expression, Purification and Functional
Evaluation. Mol Biotechnol. 2009, 41(2):138-44.
9  Guo G, Jia KR, Shi Y, Liu XF, Liu KY, Qi W, Guo Y, Zhang WJ, Wang T,
Xiao B, Zou QM. Psychological stress enhances the colonization of the
stomach by H.pylori in the BALB/c mouse.Sress. 2009, 12(6): 478 – 485.
10 Xiao B, Li W, Guo G, Li BS, Liu Z, Tang B, Mao XH, Zou QM. Screening and
identification of natural antisense transcripts in H.pylori  by a novel
approach based on RNase I protection assay. Mol Biol Rep. 2009
Sep;36(7):1853-8
11 Liu XF, Shi Y, Zhang JY, Zhuang Y,Jia KR, Mao XH, Guo Y, Liu T, Liu Z,
Wu C, Zhang WJ, Zhou WY, Guo G, Zou QM. Efficient adenovirus-mediated gene
transfer to gastric issue by oral administration. J Gene Med.
2009 Sep 15.
12 Guo Y, Guo G, Mao X, Zhang W, Xiao J, Tong W, Liu T, Xiao B, Liu X, Feng
Y, Zou Q. Functional identification of HugZ, a heme oxygenase from
H.pylori. BMC Microbiol. 2008 Dec 17;8(1):226. [Epub ahead of print]
13 Li HX, Mao XH, Shi Y, Ma Y, Wu YN, Zhang WJ, Luo P, Yu S, Zhou WY, Guo
Y, Wu C, Guo G, Zou
QM. Screening and identification of a novel B-cell neutralizing epitope
from H.pylori UreB. Vaccine, 2008 Dec
9;26(52):6945-9.
14 Wu C, Shi Y, Guo H, Zou WY, Guo G, Xie QH, Mao XH, Tong WD, Zou QM.
Protection against H.pylori
i infection in mongolian gerbil by intragastric or intramuscular
administration of H.pylori multicomponent vaccine. Helicobacter.
2008,13(3):191-9.
15 Zeng H, Guo G, Mao XH, De Tong W, Zou QM. Proteomic Insights into
H.pylori Coccoid Forms Under
Oxidative Stress. Curr Microbiol. 2008, 57: 281–286.
16 Wang H, Mao X, Ding H, Zou Q, Peng X.. Epidemiological survey on
Escherichia coli O157 in Chongqing and Three-Gorge Reservoir Areas of
P.R.China. Vet Res Commun. 2008, 32(6):449-61.
17 Ma Y, Mao X, Li J, Li H, Feng Y, Chen H, Luo P, Gu J, Yu S, Zeng H, Guo
G, Yang K, Zou Q. Engineering
an anti-Stx2 antibody to control severe infections of EHEC O157:H7.
Immunology Letters. 2008,121(2):110-5
18 An antimicrobial peptide with antimicrobial activity against H.pylori, 
Lihua Chen, Yuhong Li, Jianxu Li, Xueqing Xu, Ren Lai, Quanming Zou.
Peptides, 2007, 28:1527-1531.
19 Shi Y, Wu C, Zhou WY, Mao XH, Guo G, Zou QM. Identification of H-2(d)
restricted Th epitopes in Urease
B subunit of H.pylori Vaccine. 2007 25(14): 2583-2590
20Yang J,  Zhang  W,Liu K, Jing  S,Guo G,Luo P,Zou Q.  Expression,
purification, and characterization of recombinant human interleukin 24 in
Escherichia coli. Protein Expr Purif. 2007 June ;53(2):339-345
21 Wang  Qirui,  Quan-Ming  Zou,  et  al.  Expression, 
refolding,purification  and  bioactivity  of  recombination bifunctional
protein,hIL-2/GM-CSF. Protein Expr Purif, 2005, 39: 131-136.
22 Qiang FENG, Jun YANG, Ping LUO, Wei-Jun ZHANG, and Quan-Ming
ZOU*LT(K63/R72), a New Double Mutant of Escherichia coli Heat-labile
Enterotoxin, Exhibits Characters More Closely to LT(K63) Than LT(R72). Acta
Biochim Biophys Sin, 2005,37(2):126-132.
23 Yu  Hong,  Xu-Hu  Mao,  Wei-Kun  Zeng,  Li-Ming  Ma,  Shen-Rong  Jing, 
Quan-Ming  Zou.  Restriction fragment length polymorphism of adhesion gene
H.pylori  A from different H.pylori  of Chongqing, P.R.China
World J Gastroenterol. 2005.11(17): 2647-52
24 Shi Y*, Liu XF*, Zhuang Y, Zhang JY, Liu T, Wu C, Mao XH, Jia KR, Wang
FJ, Guo H, Zhao Z, Liu KY, Xiao B, Guo Y, Zhang WJ, Zhou WY,Guo G, Zou QM.
H.pylori-induced Th17 responses modulate Th1 cell responses, benefit
bacterial growth and contribute to pathology in mice. J Immunol 2010; 184,
5121-9
第八届国际生物医药产业发展创新论坛